MovDisordV3, Main, Curation, bibRecord, 004279

Sublingual Atropine for sialorrhea secondary to parkinsonism: A pilot study

Identifieur interne : 004279 ( Main/Curation ); précédent : 004278; suivant : 004280

Sublingual Atropine for sialorrhea secondary to parkinsonism: A pilot study

Auteurs : H. Christopher Hyson [Canada] ; Andrew M. Johnson [Canada] ; Mandar S. Jog [Canada]

Source :

Movement Disorders [ 0885-3185 ] ; 2002-11.

RBID : ISTEX:07A65F99973DA9BFA8C22CFE208BE2B92BA3D355

Descripteurs français

Pascal (Inist)
- Atropine, Chimiothérapie, Etude préalable, Homme, Parasympatholytique, Parkinson maladie, Sialorrhée, Traitement, Voie sublinguale.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Administration, Sublingual, Aged, Aged, 80 and over, Atropine, Atropine (administration & dosage), Atropine (adverse effects), Chemotherapy, Delusions (chemically induced), Female, Hallucinations (chemically induced), Human, Humans, Male, Middle Aged, Parasympatholytic, Parkinson disease, Parkinson's disease, Parkinsonian Disorders (drug therapy), Pilot Projects, Previous study, Salivation (drug effects), Sialorrhea, Sialorrhea (drug therapy), Sublingual administration, Treatment, Treatment Outcome, atropine, sialorrhea.
MESH :
- chemical , administration & dosage : Atropine.
- chemical , adverse effects : Atropine.
- chemically induced : Delusions, Hallucinations.
- drug effects : Salivation.
- drug therapy : Parkinsonian Disorders, Sialorrhea.
- Administration, Sublingual, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Pilot Projects, Treatment Outcome.

Abstract

Sialorrhea is a relatively common symptom in idiopathic Parkinson's disease and related conditions for which most of the accepted treatments are either highly invasive or may cause substantial systemic side effects. This study describes an open‐label pilot study of sublingual atropine drops for the treatment of sialorrhea in 7 patients (6 with Parkinson's disease, 1 with progressive supranuclear palsy). Participants demonstrated statistically significant declines in saliva production, both objectively and subjectively. Self‐reported drooling severity showed a significant decline between baseline and 180 minutes, t(6) = 3.240 P < 0.025 (η2 = 0.636), and between baseline and 1 week, t(6) = 4.583 P < 0.005 (η2 = 0.778). Objectively measured saliva production decreased significantly between baseline and the 1‐week follow‐up, t(6) = 2.711 P < 0.05 (η2 = 0.551). Delirium occurred in 1 patient (concurrent with a urinary tract infection), and 2 patients experienced worsening of hallucinations (active hallucinosis was concealed by both individuals to allow participation in the trial). The remaining trial participants did not experience any anticholinergic side effects. This trial shows that, in selected patient populations, sublingual atropine is a simple and inexpensive treatment for sialorrhea associated with parkinsonism. © 2002 Movement Disorder Society

Url:

https://api.istex.fr/document/07A65F99973DA9BFA8C22CFE208BE2B92BA3D355/fulltext/pdf

DOI: 10.1002/mds.10276

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002D52
to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :002D52
to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002B70
to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003904
to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :003904
to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003925
to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000947
to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :000947
to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000947
to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :006284
to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002567
to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :000754
to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002600
to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :006639

Links to Exploration step

ISTEX:07A65F99973DA9BFA8C22CFE208BE2B92BA3D355

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sublingual Atropine for sialorrhea secondary to parkinsonism: A pilot study</title>
<author><name sortKey="Hyson, H Christopher" sort="Hyson, H Christopher" uniqKey="Hyson H" first="H. Christopher" last="Hyson">H. Christopher Hyson</name>
</author>
<author><name sortKey="Johnson, Andrew M" sort="Johnson, Andrew M" uniqKey="Johnson A" first="Andrew M." last="Johnson">Andrew M. Johnson</name>
</author>
<author><name sortKey="Jog, Mandar S" sort="Jog, Mandar S" uniqKey="Jog M" first="Mandar S." last="Jog">Mandar S. Jog</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:07A65F99973DA9BFA8C22CFE208BE2B92BA3D355</idno>
<date when="2002" year="2002">2002</date>
<idno type="doi">10.1002/mds.10276</idno>
<idno type="url">https://api.istex.fr/document/07A65F99973DA9BFA8C22CFE208BE2B92BA3D355/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002D52</idno>
<idno type="wicri:Area/Istex/Curation">002D52</idno>
<idno type="wicri:Area/Istex/Checkpoint">002B70</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Hyson H:sublingual:atropine:for</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:12465075</idno>
<idno type="wicri:Area/PubMed/Corpus">003904</idno>
<idno type="wicri:Area/PubMed/Curation">003904</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003925</idno>
<idno type="wicri:Area/Ncbi/Merge">000947</idno>
<idno type="wicri:Area/Ncbi/Curation">000947</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000947</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Hyson H:sublingual:atropine:for</idno>
<idno type="wicri:Area/Main/Merge">006284</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:03-0040823</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002567</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000754</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002600</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Hyson H:sublingual:atropine:for</idno>
<idno type="wicri:Area/Main/Merge">006639</idno>
<idno type="wicri:Area/Main/Curation">004279</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Sublingual Atropine for sialorrhea secondary to parkinsonism: A pilot study</title>
<author><name sortKey="Hyson, H Christopher" sort="Hyson, H Christopher" uniqKey="Hyson H" first="H. Christopher" last="Hyson">H. Christopher Hyson</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Movement Disorders Program, London Health Sciences Centre, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Johnson, Andrew M" sort="Johnson, Andrew M" uniqKey="Johnson A" first="Andrew M." last="Johnson">Andrew M. Johnson</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>University of Western Ontario, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jog, Mandar S" sort="Jog, Mandar S" uniqKey="Jog M" first="Mandar S." last="Jog">Mandar S. Jog</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Movement Disorders Program, London Health Sciences Centre, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2002-11">2002-11</date>
<biblScope unit="vol">17</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="1318">1318</biblScope>
<biblScope unit="page" to="1320">1320</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">07A65F99973DA9BFA8C22CFE208BE2B92BA3D355</idno>
<idno type="DOI">10.1002/mds.10276</idno>
<idno type="ArticleID">MDS10276</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Sublingual</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Atropine</term>
<term>Atropine (administration & dosage)</term>
<term>Atropine (adverse effects)</term>
<term>Chemotherapy</term>
<term>Delusions (chemically induced)</term>
<term>Female</term>
<term>Hallucinations (chemically induced)</term>
<term>Human</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parasympatholytic</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Parkinsonian Disorders (drug therapy)</term>
<term>Pilot Projects</term>
<term>Previous study</term>
<term>Salivation (drug effects)</term>
<term>Sialorrhea</term>
<term>Sialorrhea (drug therapy)</term>
<term>Sublingual administration</term>
<term>Treatment</term>
<term>Treatment Outcome</term>
<term>atropine</term>
<term>sialorrhea</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Atropine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Atropine</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Delusions</term>
<term>Hallucinations</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Salivation</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinsonian Disorders</term>
<term>Sialorrhea</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Sublingual</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pilot Projects</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Atropine</term>
<term>Chimiothérapie</term>
<term>Etude préalable</term>
<term>Homme</term>
<term>Parasympatholytique</term>
<term>Parkinson maladie</term>
<term>Sialorrhée</term>
<term>Traitement</term>
<term>Voie sublinguale</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Sialorrhea is a relatively common symptom in idiopathic Parkinson's disease and related conditions for which most of the accepted treatments are either highly invasive or may cause substantial systemic side effects. This study describes an open‐label pilot study of sublingual atropine drops for the treatment of sialorrhea in 7 patients (6 with Parkinson's disease, 1 with progressive supranuclear palsy). Participants demonstrated statistically significant declines in saliva production, both objectively and subjectively. Self‐reported drooling severity showed a significant decline between baseline and 180 minutes, t(6) = 3.240 P < 0.025 (η2 = 0.636), and between baseline and 1 week, t(6) = 4.583 P < 0.005 (η2 = 0.778). Objectively measured saliva production decreased significantly between baseline and the 1‐week follow‐up, t(6) = 2.711 P < 0.05 (η2 = 0.551). Delirium occurred in 1 patient (concurrent with a urinary tract infection), and 2 patients experienced worsening of hallucinations (active hallucinosis was concealed by both individuals to allow participation in the trial). The remaining trial participants did not experience any anticholinergic side effects. This trial shows that, in selected patient populations, sublingual atropine is a simple and inexpensive treatment for sialorrhea associated with parkinsonism. © 2002 Movement Disorder Society</div>
</front>
</TEI>
<double idat="0885-3185:2002:Hyson H:sublingual:atropine:for"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Sublingual atropine for sialorrhea secondary to parkinsonism: A pilot study</title>
<author><name sortKey="Hyson, H Christopher" sort="Hyson, H Christopher" uniqKey="Hyson H" first="H. Christopher" last="Hyson">H. Christopher Hyson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Movement Disorders Program, London Health Sciences Centre</s1>
<s2>London, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>London, Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Johnson, Andrew M" sort="Johnson, Andrew M" uniqKey="Johnson A" first="Andrew M." last="Johnson">Andrew M. Johnson</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Western Ontario</s1>
<s2>London, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>University of Western Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jog, Mandar S" sort="Jog, Mandar S" uniqKey="Jog M" first="Mandar S." last="Jog">Mandar S. Jog</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Movement Disorders Program, London Health Sciences Centre</s1>
<s2>London, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>London, Ontario</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">03-0040823</idno>
<date when="2002">2002</date>
<idno type="stanalyst">PASCAL 03-0040823 INIST</idno>
<idno type="RBID">Pascal:03-0040823</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002567</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000754</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002600</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Hyson H:sublingual:atropine:for</idno>
<idno type="wicri:Area/Main/Merge">006639</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Sublingual atropine for sialorrhea secondary to parkinsonism: A pilot study</title>
<author><name sortKey="Hyson, H Christopher" sort="Hyson, H Christopher" uniqKey="Hyson H" first="H. Christopher" last="Hyson">H. Christopher Hyson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Movement Disorders Program, London Health Sciences Centre</s1>
<s2>London, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>London, Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Johnson, Andrew M" sort="Johnson, Andrew M" uniqKey="Johnson A" first="Andrew M." last="Johnson">Andrew M. Johnson</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Western Ontario</s1>
<s2>London, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>University of Western Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jog, Mandar S" sort="Jog, Mandar S" uniqKey="Jog M" first="Mandar S." last="Jog">Mandar S. Jog</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Movement Disorders Program, London Health Sciences Centre</s1>
<s2>London, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>London, Ontario</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2002">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Atropine</term>
<term>Chemotherapy</term>
<term>Human</term>
<term>Parasympatholytic</term>
<term>Parkinson disease</term>
<term>Previous study</term>
<term>Sialorrhea</term>
<term>Sublingual administration</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Sialorrhée</term>
<term>Atropine</term>
<term>Parasympatholytique</term>
<term>Voie sublinguale</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Homme</term>
<term>Etude préalable</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Sialorrhea is a relatively common symptom in idiopathic Parkinson's disease and related conditions for which most of the accepted treatments are either highly invasive or may cause substantial systemic side effects. This study describes an open-label pilot study of sublingual atropine drops for the treatment of sialorrhea in 7 patients (6 with Parkinson's disease, I with progressive supranuclear palsy). Participants demonstrated statistically significant declines in saliva production, both objectively and subjectively. Self-reported drooling severity showed a significant decline between baseline and 180 minutes, t(6) = 3.240 P < 0.025 (η<sup>2</sup>
 = 0.636), and between baseline and I week, t(6) = 4.583 P < 0.005 (η<sup>2</sup>
 = 0.778). Objectively measured saliva production decreased significantly between baseline and the 1-week follow-up, t(6) = 2.711 P < 0.05 (η<sup>2</sup>
 = 0.551). Delirium occurred in 1 patient (concurrent with a urinary tract infection), and 2 patients experienced worsening of hallucinations (active hallucinosis was concealed by both individuals to allow participation in the trial). The remaining trial participants did not experience any anticholinergic side effects. This trial shows that, in selected patient populations, sublingual atropine is a simple and inexpensive treatment for sialorrhea associated with parkinsonism.</div>
</front>
</TEI>
</INIST>
<ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sublingual Atropine for sialorrhea secondary to parkinsonism: A pilot study</title>
<author><name sortKey="Hyson, H Christopher" sort="Hyson, H Christopher" uniqKey="Hyson H" first="H. Christopher" last="Hyson">H. Christopher Hyson</name>
</author>
<author><name sortKey="Johnson, Andrew M" sort="Johnson, Andrew M" uniqKey="Johnson A" first="Andrew M." last="Johnson">Andrew M. Johnson</name>
</author>
<author><name sortKey="Jog, Mandar S" sort="Jog, Mandar S" uniqKey="Jog M" first="Mandar S." last="Jog">Mandar S. Jog</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:07A65F99973DA9BFA8C22CFE208BE2B92BA3D355</idno>
<date when="2002" year="2002">2002</date>
<idno type="doi">10.1002/mds.10276</idno>
<idno type="url">https://api.istex.fr/document/07A65F99973DA9BFA8C22CFE208BE2B92BA3D355/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002D52</idno>
<idno type="wicri:Area/Istex/Curation">002D52</idno>
<idno type="wicri:Area/Istex/Checkpoint">002B70</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Hyson H:sublingual:atropine:for</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:12465075</idno>
<idno type="wicri:Area/PubMed/Corpus">003904</idno>
<idno type="wicri:Area/PubMed/Curation">003904</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003925</idno>
<idno type="wicri:Area/Ncbi/Merge">000947</idno>
<idno type="wicri:Area/Ncbi/Curation">000947</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000947</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Hyson H:sublingual:atropine:for</idno>
<idno type="wicri:Area/Main/Merge">006284</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Sublingual Atropine for sialorrhea secondary to parkinsonism: A pilot study</title>
<author><name sortKey="Hyson, H Christopher" sort="Hyson, H Christopher" uniqKey="Hyson H" first="H. Christopher" last="Hyson">H. Christopher Hyson</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Movement Disorders Program, London Health Sciences Centre, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Johnson, Andrew M" sort="Johnson, Andrew M" uniqKey="Johnson A" first="Andrew M." last="Johnson">Andrew M. Johnson</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>University of Western Ontario, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jog, Mandar S" sort="Jog, Mandar S" uniqKey="Jog M" first="Mandar S." last="Jog">Mandar S. Jog</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Movement Disorders Program, London Health Sciences Centre, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2002-11">2002-11</date>
<biblScope unit="vol">17</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="1318">1318</biblScope>
<biblScope unit="page" to="1320">1320</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">07A65F99973DA9BFA8C22CFE208BE2B92BA3D355</idno>
<idno type="DOI">10.1002/mds.10276</idno>
<idno type="ArticleID">MDS10276</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Sublingual</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Atropine (administration & dosage)</term>
<term>Atropine (adverse effects)</term>
<term>Delusions (chemically induced)</term>
<term>Female</term>
<term>Hallucinations (chemically induced)</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson's disease</term>
<term>Parkinsonian Disorders (drug therapy)</term>
<term>Pilot Projects</term>
<term>Salivation (drug effects)</term>
<term>Sialorrhea (drug therapy)</term>
<term>Treatment Outcome</term>
<term>atropine</term>
<term>sialorrhea</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Atropine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Atropine</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Delusions</term>
<term>Hallucinations</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Salivation</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinsonian Disorders</term>
<term>Sialorrhea</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Sublingual</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pilot Projects</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Sialorrhea is a relatively common symptom in idiopathic Parkinson's disease and related conditions for which most of the accepted treatments are either highly invasive or may cause substantial systemic side effects. This study describes an open‐label pilot study of sublingual atropine drops for the treatment of sialorrhea in 7 patients (6 with Parkinson's disease, 1 with progressive supranuclear palsy). Participants demonstrated statistically significant declines in saliva production, both objectively and subjectively. Self‐reported drooling severity showed a significant decline between baseline and 180 minutes, t(6) = 3.240 P < 0.025 (η2 = 0.636), and between baseline and 1 week, t(6) = 4.583 P < 0.005 (η2 = 0.778). Objectively measured saliva production decreased significantly between baseline and the 1‐week follow‐up, t(6) = 2.711 P < 0.05 (η2 = 0.551). Delirium occurred in 1 patient (concurrent with a urinary tract infection), and 2 patients experienced worsening of hallucinations (active hallucinosis was concealed by both individuals to allow participation in the trial). The remaining trial participants did not experience any anticholinergic side effects. This trial shows that, in selected patient populations, sublingual atropine is a simple and inexpensive treatment for sialorrhea associated with parkinsonism. © 2002 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
</double>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004279 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 004279 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Curation
   |type=    RBID
   |clé=     ISTEX:07A65F99973DA9BFA8C22CFE208BE2B92BA3D355
   |texte=   Sublingual Atropine for sialorrhea secondary to parkinsonism: A pilot study
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Sublingual Atropine for sialorrhea secondary to parkinsonism: A pilot study

Sublingual Atropine for sialorrhea secondary to parkinsonism: A pilot study

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri